other material
confidence high
sentiment positive
materiality 0.60
Enveric corrects EB-003 binding affinity data, shows 1000x greater potency than previously reported
Enveric Biosciences, Inc.
- EB-003 exhibits 5-HT2A partial agonism with Ki of 0.2 µM (corrected from 0.2 mM) – 1000x higher binding affinity.
- EB-003 binds 5-HT1A receptor with Ki of 3.3 µM (corrected from 3.3 mM).
- Enveric to initiate preclinical IND-enabling activities in early 2024 for EB-003.
- EB-003 selected as lead candidate from EVM301 Series; designed to promote neuroplasticity without hallucinations.
- Company used PsyAI platform to screen 51 analogs; EB-003 showed no significant head-twitch response in mice.